Since ESC and ACC/AHA are examining hard LDL-C targets for patients at risk for ASCVD, how does ODYSSEY Outcomes help inform cardiologists about the rationale for PCSK9-mediated lowering to achieve ultra-low levels (i.e. <50 mg/dL) of LDL-C?

Since ESC and ACC/AHA are examining hard LDL-C targets for patients at risk for ASCVD, how does ODYSSEY Outcomes help inform cardiologists about the rationale for PCSK9-mediated lowering to achieve ultra-low levels (i.e. <50 mg/dL) of LDL-C?

CLICK HERE FOR CME CREDIT

Since ESC and ACC/AHA are examining hard LDL-C targets for patients at risk for ASCVD, how does ODYSSEY Outcomes help inform cardiologists about the rationale for PCSK9-mediated lowering to achieve ultra-low levels (i.e.

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology Université Paris – Diderot, Sorbonne-Paris Cité Professor, National Heart and Lung Institute Imperial College, London, UK Director, Coronary Care Unit Hôpital Bichat Paris, France